

SPARC/Sec/SE/2018-19/007

8th May 2018

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 8th May 2018.

The Board of Directors of the Company at their meeting held from 04:45 pm to 06:45 pm today, *inter alia*, took on record and duly approved the Audited Financial Results for the quarter and year ended 31st March, 2018 which are enclosed along with the Auditors' Report on the financial statements of the Company for the financial year ended 31st March 2018, as **Annexure 1.**

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2018 is also enclosed.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Sun Pharma Advanced Research Company Ltd**

A handwritten signature in black ink, appearing to read "Debashis Dey", with a horizontal line underneath.

Debashis Dey
Company Secretary

Date: 8th May 2018

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited.,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.


Dear Sir/ Madam,

Sub : Declaration in terms of regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we confirm that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year 2017-18.

Thanking you,

Yours faithfully,
For **Sun Pharma Advanced Research Company Ltd**



Chetan Rajpara
Chief Financial Officer

Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
Sun Pharma Advanced Research Company Limited,

1. We have audited the accompanying statement of quarterly standalone financial results of Sun Pharma Advanced Research Company Limited ('the Company') for the quarter ended March 31, 2018 and for the year ended March 31, 2018 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ('the Circular'). The standalone financial results for the quarter ended March 31, 2018 and year ended March 31, 2018 have been prepared on the basis of the standalone financial results for the nine-month period ended December 31, 2017, the audited annual standalone Ind AS financial statements as at and for the year ended March 31, 2018, and the relevant requirements of the Regulation and the Circular, which are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these standalone financial results based on our review of the standalone financial results for the nine-month period ended December 31, 2017 which was prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 Interim Financial Reporting, specified under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual standalone Ind AS financial statements as at and for the year ended March 31, 2018; and the relevant requirements of the Regulation and the Circular.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly standalone financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of the Regulation read with the Circular, in this regard; and
 - ii. give a true and fair view of the total comprehensive income (comprising of net loss and other comprehensive income) and other financial information for the quarter ended March 31, 2018 and for the year ended March 31, 2018.
4. The comparative financial information of the Company for the corresponding quarter and year ended March 31, 2017 included in these standalone Ind AS financial results, are based on the previously issued standalone financial results prepared in accordance with the recognition and measurement principles of the Accounting Standards, specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and audited by the predecessor auditor whose report for the corresponding quarter and the year ended March 31, 2017 dated May 05, 2017 expressed an unmodified opinion on those standalone financial results, as adjusted for the differences in the accounting principles adopted by the Company on transition to the Ind AS, which have been audited by us.



S R B C & CO LLP

Chartered Accountants

Sun Pharma Advanced Research Company Limited

Page 2 of 2

5. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2018 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2018 and the published year-to-date figures up to December 31, 2017, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under the Regulation and the Circular.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003

per Ravi Bansal
Partner

Membership No.: 49365



Place: Mumbai

Date of signature: May 08, 2018

Sun Pharma Advanced Research Company Limited

Regd Office: Sun Pharma Advanced Research Centre,
Akota Road, Akota, Vadodara – 390 020. Tel. : 0265-2330815
CIN : L73100GJ2006PLC047837 Website : www.sparc.life

Statement of Audited Financial Results for the Quarter and Year Ended March 31, 2018

₹ in Lakhs

Particulars	Quarter ended			Year ended	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
	Audited	Unaudited	Audited	Audited	Audited
	(Refer Note 7)		(Refer Note 7)		
Revenue from Operations	2,009	1,942	4,160	7,826	18,102
Other Income	52	216	378	494	1,372
Total Income	2,061	2,158	4,538	8,320	19,474
Expenses					
Cost of Materials Consumed	515	526	301	2,681	2,516
Employee Benefits Expense	2,430	2,472	1,971	10,093	8,430
Clinical Trial Expenses	1,136	3,134	3,807	11,736	13,663
Finance Costs	1	2	3	12	182
Depreciation and Amortisation Expense	202	202	208	818	824
Other Expenses	2,427	1,629	1,437	7,578	5,763
Total Expenses	6,711	7,965	7,727	32,918	31,378
Profit / (Loss) before exceptional items and tax	(4,650)	(5,807)	(3,189)	(24,598)	(11,904)
Exceptional items (Income) (Refer Note 4)	4,898	-	-	4,898	-
Profit / (Loss) before tax	248	(5,807)	(3,189)	(19,700)	(11,904)
Tax Expense	-	-	-	-	-
Profit / (Loss) for the period	248	(5,807)	(3,189)	(19,700)	(11,904)
Other Comprehensive Income (OCI) (net of tax)					
Items that will not be reclassified to profit and loss (Net actuarial loss on employee defined benefit obligation)	(104)	(13)	(13)	(143)	(46)
Total Comprehensive Income	144	(5,820)	(3,202)	(19,843)	(11,950)
Paid-up Equity Share Capital (Face Value ₹ 1 each)	2,509	2,509	2,469	2,509	2,469
Basic and Diluted Earnings Per Share of ₹ 1 each	0.10	(2.34)	(1.30)	(7.94)	(4.84)
See accompanying notes to the financial results	Not Annualised	Not Annualised	Not Annualised		

Statement of Assets and Liabilities

₹ in Lakhs

Particulars	As at	As at
	31.03.2018	31.03.2017
	Audited	Audited
ASSETS		
A Non-current Assets		
(a) Property, Plant and Equipment	5,151	6,916
(b) Capital Work-In-Progress	327	147
(c) Other intangible assets	23	-
(d) Financial Assets		
(i) Loans	0	6
(ii) Other Financial Assets	2	2
(e) Deferred tax assets (Net)	-	-
(f) Income Tax Assets (Net)	5,332	4,324
(g) Non Current Tax Assets (Net)	2,524	32
Total Non-current Assets (A)	13,359	11,427
B Current Assets		
(a) Financial Assets		
(i) Investments	10,757	965
(ii) Trade Receivables	1,756	3,890
(iii) Cash and Cash Equivalents	20	6,358
(iv) Bank Balance other than Cash and Cash Equivalents	112	672
(v) Loans	58	141
(vi) Others Financial Assets	1	59
(b) Other Current Assets	4,818	3,743
Total Current Assets (B)	17,522	15,828
TOTAL ASSETS	30,881	27,255
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	2,509	2,469
(b) Other Equity	15,963	13,347
Total Equity	18,472	15,816
A Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	164	218
(b) Provisions	634	418
Total Non-current Liabilities (A)	798	636
B Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	10	41
(ii) Trade Payables	10,249	9,446
(iii) Other Financial Liabilities	181	170
(b) Other Current Liabilities	761	811
(c) Provisions	410	335
Total Current Liabilities (B)	11,611	10,803
TOTAL LIABILITIES	30,881	27,255



Sun Pharma Advanced Research Company Limited

Regd Office: Sun Pharma Advanced Research Centre,
Akota Road, Akota, Vadodara – 390 020. Tel. : 0265-2330815
CIN : L73100GJ2006PLC047837 Website : www.sparc.life

Notes :

- 1 The above audited financial results are as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and have been taken on record by the Board of Directors at its meeting held on May 8, 2018 after being reviewed by the Audit Committee.
- 2 The Company adopted Indian Accounting Standard ('Ind AS') from April 1, 2017 and the date of transition is April 1, 2016. The impact of adjustments arising on transition has been accounted for in opening reserves and the comparative period results have been restated accordingly.
- 3 The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- 4 Exceptional item represents sale of existing premises of the Company at Tandajja, Vadodara
- 5 The Securities Allotment Committee of the Company in its meeting held on 15th December 2017, has allotted 4,040,404 fully paid up equity shares of FV ₹ 1 each of the Company pursuant to conversion of equivalent number of warrants held by the respective warrant holders upon exercise of 'conversion option' by the respective concerned warrant holders. Consequent to the above, the paid-up capital of the Company has increased from ₹ 24,68,95,991 divided into 24,68,95,991 equity shares of FV ₹ 1 each to ₹ 25,09,36,395 divided into 25,09,36,395 equity shares of FV ₹ 1 each, during the year. As on 31st March 2018, the Company had 11,111,111 outstanding warrants, which are yet to be converted into equity shares of the Company.
- 6 Reconciliation of Profit / (Loss) and equity reported in accordance with Indian GAAP to Total Comprehensive Income and equity in accordance with Ind AS for the quarter and year ended March 31, 2017 is given below:

Particulars	₹ in Lakhs	
	Quarter ended	Year ended
	31.03.2017 Audited	31.03.2017 Audited
	(Refer Note 7)	
Profit / (Loss) as per Previous GAAP	(3,227)	(12,027)
Add / (Less) : Adjustments for GAAP Differences		
Share Issue Expenses transferred to other equity	20	68
Reclassification of Net Actuarial loss on employee defined benefit obligations to OCI	13	46
Fair Value of Investments	5	9
Impact of taxes in respect of the above adjustments	-	-
Profit / (Loss) as per Ind AS (before OCI)	(3,189)	(11,904)
Reclassification of Net Actuarial loss on employee defined benefit obligations to OCI	(13)	(46)
Total Comprehensive Income	(3,202)	(11,950)

Particulars	As at
	31.03.2017 Audited
Reconciliation of total equity	
Total equity as per previous GAAP	15,965
Add / (less) : Adjustments for GAAP differences	
Share Issue Expenses transferred to other equity	(158)
Fair Value of Investments	9
Total equity as per Ind AS	15,816

- 7 Figures for the quarter ended March 31, 2018 and March 31, 2017 are balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the respective financial years.
- 8 Previous period figures have been regrouped / rearranged, wherever necessary, to correspond to current period's presentation.

Mumbai, May 8, 2018



By order of the Board

(Signature)
Dilip S. Shanghvi
Chairman and Managing Director